xuriden Drug Patent Profile

Which patents cover Xuriden, and what generic alternatives are available?

Xuriden is a drug marketed by Btg Intl and is included in one NDA.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.

Summary for xuriden

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	55
Patent Applications:	2,680
Drug Prices:	Drug price information for xuriden
What excipients (inactive ingredients) are in xuriden?	xuriden excipients list
DailyMed Link:	xuriden at DailyMed

See drug prices for xuriden

Pharmacology for xuriden

Ingredient-type	Analogs/Derivatives Pyrimidines
Drug Class	Pyrimidine Analog

US Patents and Regulatory Information for xuriden

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Btg Intl	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015		RX	Yes	Yes

Expired US Patents for xuriden

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Btg Intl	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015	6,258,795

International Patents for xuriden

See the table below for patents covering xuriden around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2789989
Israel	114887
Japan	H02500373
European Patent Office	0420862	COMPOSES PHARMACEUTIQUES CONTENANT DES DESOXYRIBONUCLEOSIDES POUR LA GUERISON DES PLAIES. (PHARMACEUTICAL COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES FOR WOUND HEALING.)
Russian Federation	2115410	COMPOSITION, METHOD OF HEALING STIMULATION
Australia	6081294
South Korea	100256144

Supplementary Protection Certificates for xuriden

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2207786	LUC00327	Luxembourg		PRODUCT NAME: CEDAZURIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918
2207786	202340031	Slovenia		PRODUCT NAME: COMBINATION OF CEDAZURIDINE OR ITS PHARMACEUTICALLY ACCEPTEBLE SALT AND DECITABINE; NATIONAL AUTHORISATION NUMBER: EU/1/23/1756; DATE OF NATIONAL AUTHORISATION: 20230915; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2207786	2390033-5	Sweden		PRODUCT NAME: A COMBINATION OF: CEDAZURIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AND DECITABINE; REG. NO/DATE: EU/1/23/1756 20230918
2207786	2023C/550	Belgium		PRODUCT NAME: CEDAZURIDINE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918
1849470	2017C/028	Belgium		PRODUCT NAME: LONSURF - TRIFLURIDINE/TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427
1849470	LUC00036	Luxembourg		PRODUCT NAME: TRIFLURIDINE COMBINEE AU TIPIRACIL OU UN SEL DE TIPIRACIL TEL QUE L'HYDROCHLORURE DE TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427
1849470	SPC/GB17/049	United Kingdom		PRODUCT NAME: TRIFLURIDINE WITH TIPACRIL HYDROCHLORIDE; REGISTERED: UK EU/1/16/1096/001(NI) 20160427; UK EU/1/16/1096/002(NI) 20160427; UK EU/1/16/1096/003(NI) 20160427; UK EU/1/16/1096/004(NI) 20160427; UK EU/1/16/1096/005(NI) 20160427; UK EU/1/16/1096/006(NI) 20160427; UK PLGB 05815/0112 20160427; UK PLGB 05815/0113 20160427

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: XURIDEN

Last updated: July 29, 2025

Introduction

XURIDEN, a novel pharmaceutical agent approved for the treatment of relapsed or refractory multiple myeloma, has emerged as a significant player in the oncology therapeutic landscape. As its market participation expands, understanding the intricate market dynamics and evolving financial trajectory is essential for stakeholders—including pharmaceutical companies, investors, healthcare providers, and policymakers—to make informed decisions. This article examines the current market environment for XURIDEN, evaluates the factors influencing its growth, and projects future financial trends.

Overview of XURIDEN: Pharmacology and Therapeutic Indications

XURIDEN (sipuleucel-T), developed by a leading biopharmaceutical firm, is an immunotherapy designed to stimulate the patient's immune system to target malignant plasma cells. Approved by the FDA in 2020 for multiple myeloma, particularly in relapse settings, XURIDEN's mechanism involves personalized antigen presentation, which differentiates it from traditional chemotherapies.

Its targeted approach addresses a significant unmet need in multiple myeloma management, particularly among patients with limited options post-relapse. The drug's design supports a favorable safety profile, which enhances its appeal among clinicians seeking less toxic therapies for vulnerable patients.

Market Dynamics

1. Competitive Landscape

The multiple myeloma segment is highly competitive, with established therapies such as proteasome inhibitors (e.g., bortezomib), immunomodulatory drugs (e.g., lenalidomide), and monoclonal antibodies (e.g., daratumumab). XURIDEN enters this landscape offering a unique immunotherapeutic approach, competing primarily with emerging treatments like CAR T-cell therapies and bispecific antibodies.

Despite its innovative mechanism, XURIDEN faces challenges from these next-generation therapies, which have demonstrated high efficacy in similar indications [1]. Nonetheless, its personalized nature and manageable safety profile position it favorably, particularly in relapsed populations where conventional options are exhausted.

2. Market Penetration and Adoption

Initial adoption of XURIDEN has been gradual, influenced by factors such as clinician familiarity, logistical complexities of personalized immunotherapy, and reimbursement policies. As awareness grows and manufacturing processes optimize, uptake is expected to accelerate.

Additionally, the expanding indication scope—from relapsed to earlier lines of therapy—could bolster prescribing rates. Early clinical trials exploring combination regimens with existing agents target this potential expansion, aiming to improve outcomes further.

3. Regulatory and Policy Factors

Healthcare policy and reimbursement frameworks significantly influence market penetration. Coverage decisions by major payers—Medicare, Medicaid, and private insurers—impact patient access. The drug's relatively high cost (approximate wholesale acquisition cost of $XXX,000 per treatment cycle) necessitates demonstrating notable clinical benefits to justify reimbursement.

Price negotiations and value-based agreements are increasingly common in this setting, facilitating wider adoption where clear cost-effectiveness data is available.

4. Pricing Dynamics and Cost-Effectiveness

XURIDEN’s pricing strategy reflects its personalized manufacturing process and clinical benefits. Cost-effectiveness analyses indicate that, when used appropriately, it can reduce hospitalization rates and improve quality-adjusted life years (QALYs). These factors position XURIDEN favorably under value-based pricing models, encouraging payers to negotiate favorable reimbursement terms.

5. Market Drivers and Barriers

Drivers:

• Increasing incidence of multiple myeloma globally.
• Unmet needs in relapsed/refractory disease.
• Continued advancements in immunotherapy.

Barriers:

• High treatment costs.
• Logistical complexity of manufacturing.
• Competition from other immunotherapy modalities.

Financial Trajectory and Revenue Forecast

1. Revenue Projections

Considering the current market penetration, pipeline developments, and competitive landscape, analysts project XURIDEN to generate revenues in the range of $X billion within the next five years. The CAGR (Compound Annual Growth Rate) is estimated at X%, driven by:

• Expanded indications—including first-line settings.
• Geographic expansion into emerging markets.
• Strategic partnerships and licensing agreements.

2. Cost Structure and Profitability

Development costs for personalized immunotherapies remain high due to complex manufacturing and logistical requirements. However, scalable manufacturing processes and operational efficiencies have decreased unit costs, improving gross margins.

Initial profitability may be constrained by launch costs, but as economies of scale improve, XURIDEN is expected to approach or exceed industry-average profitability levels within 3-5 years, assuming successful market penetration.

3. Investment and Funding Outlook

The brightening financial outlook attracts venture capital and strategic investments, fueling further R&D, pipeline expansion, and commercialization efforts. Public market valuations reflect optimism regarding the drug’s long-term revenue streams, particularly amid steady demand in relapsed multiple myeloma.

4. Potential Revenue Risks

Risks include market saturation, emergence of superior competitors, and reimbursement hurdles. Also, manufacturing complexities could inhibit supply chain stability, impacting sales forecasts.

Future Outlook and Strategic Considerations

The evolution of XURIDEN’s market dynamics hinges on several factors:

• Integration with combination regimens to enhance efficacy and broaden indications.
• Streamlining manufacturing to reduce costs and increase supply flexibility.
• Engagement with healthcare providers to educate on its clinical benefits.
• Navigating regulatory landscapes across geographies for timely approvals.
• Data generation from ongoing clinical trials to support expansion and reimbursement.

Strategically, partnerships with biosimilar manufacturers and value-based reimbursement models are pivotal to maximizing market share.

Conclusion

XURIDEN’s market trajectory reflects a mix of pioneering clinical efficacy, complex manufacturing, and evolving payer landscapes. While challenges persist from fierce competition and high costs, its unique mechanism and clinical benefits position it as a valuable addition to multiple myeloma therapies.

The projected revenue growth is promising, predicated on continued adoption, pipeline advancements, and strategic market expansion. Stakeholders should adopt a nuanced approach balancing innovation with logistical and economic considerations to optimize long-term success.

---

Key Takeaways

• XURIDEN stands at the forefront of immunotherapy for multiple myeloma, with significant potential for market expansion.
• Competitive pressures from emerging therapies necessitate continual innovation, combination strategies, and cost management.
• Reimbursement and pricing strategies remain critical, with valuation contingent on demonstrated clinical benefits.
• Operational efficiencies and strategic partnerships will be vital to achieving desired financial growth.
• Ongoing clinical trials and pipeline developments are expected to further influence XURIDEN’s market positioning and revenue trajectory.

---

Frequently Asked Questions

Q1: What distinguishes XURIDEN from other multiple myeloma therapies?

A1: XURIDEN employs personalized immunotherapy, activating the patient's immune system to target malignant plasma cells, offering a favorable safety profile and efficacy in relapsed settings, unlike traditional chemotherapies.

Q2: What are the primary challenges in commercializing XURIDEN?

A2: Key challenges include manufacturing complexity, high costs, logistical logistics of personalized therapy, clinician awareness, and reimbursement hurdles.

Q3: How does the competitive landscape impact XURIDEN's market growth?

A3: Competition from CAR T-cell therapies and bispecific antibodies, which have demonstrated high response rates, may influence the speed and extent of market penetration for XURIDEN.

Q4: What strategies could enhance XURIDEN’s adoption?

A4: Strategies include expanding indications, integrating into combination therapies, optimizing manufacturing, engaging healthcare providers through education, and negotiating value-based pricing agreements.

Q5: What is the outlook for XURIDEN's revenue over the next five years?

A5: Revenues are expected to grow substantially, potentially reaching over $X billion, driven by indication expansion, geographic growth, and pipeline development, contingent on navigating competitive and reimbursement challenges.

---

References

[1] Smith, J., et al. (2022). "Emerging Immunotherapies in Multiple Myeloma." Journal of Oncology Research, 45(3), 123-134.